PaxVax names Nima Farzan new CEO
"As PaxVax continues on its trajectory of growth, the board and I are confident that Nima is the right person to lead the company forward," Kelley said. "Nima is a talented commercial leader and strategist who has been instrumental in building PaxVax into a fully integrated vaccine company. Under his leadership, PaxVax has built a product portfolio, manufacturing capacity and commercial infrastructure that is capable of supplying our specialty vaccines globally.”
Farzan now has the added responsibility of global PaxVax, including management of R&D, commercial operations and manufacturing. He has many years of experience in leadership roles. Before joining PaxVax in 2011, he worked at Novartis AG for more than seven years. He held positions of increasing responsibility, including sales, development and marketing, both nationally and internationally.
Kenneth Kelley, the co-founder and previous CEO of PaxVax, will continue to serve the company as a director on PaxVax’s board of directors. He will also be an Advanced Leadership Initiative Fellow at Harvard University, where he will focus on related worldwide health issues.
"PaxVax has grown to become one of the largest U.S.-headquartered vaccine companies, and we are poised to accelerate our growth with a robust portfolio of late-stage vaccine candidates for the compelling yet overlooked markets of travel and biodefense,” Farzan said. “Ken’s vision for a company that has both a social and commercial mission has been an important catalyst in our success to date. I am honored to have been chosen by the board to lead PaxVax, and I look forward to working with our executive team and our employees to build the world’s leading specialty vaccine company.”